Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients

International Clinical Psychopharmacology

Volumn 25, Issue 2, 2010, Pages 101-106

  Löffler, Stefan ^a   Löffler Ensgraber, Mignon ^b   Fehsel, Karin ^c   Klimke, Ansgar ^a  

^a Klinikum Offenbach GmbH   (Germany)

^b European Management School   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Acute phase response; Antipsychotic; C reactive protein; Clozapine; Inflammation; Leukocyte; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; CLOZAPINE; HALOPERIDOL;

ACUTE PHASE RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; C-REACTIVE PROTEIN; CLOZAPINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 76349121032     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32833643fd     Document Type: Article

References (39)

1. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, et al. (2004). C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 24:1509-1515.
2. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al. (2004). The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37:243-265. (Pubitemid 39587052)
3. Branik E, Nitschke M (2004). Pericarditis and polyserositis as a side effect of clozapine in an adolescent girl. J Child Adolesc Psychopharmacol 14:311-314.
4. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Colombo F, Zagliani A, et al. (2001). Cytokine profiles in drug-naive schizophrenic patients. Schizophrenia Res 47:293-298.
5. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007). C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93:261-265.
6. Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454.
7. Harris EC, Barraclough B (1998). Excess mortality of mental disorder. Br J Psychiat 173:11-53.
8. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. (2005). Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 66:1116-1121.
9. Jablensky A (1986). Epidemiology of schizophrenia: a European perspective. Schizophr Bull 12:52-73.
10. Kiivet RA, Lierena A, Dahl ML, Rootslane L, Sanchez Vega J, Eklundh T, et al. (1995). Patterns of drug treatment of schizophrenic patients in estonia, spain and sweden. Br J Clin Pharmacol 40:467-476.
11. Kohen I, Afzal N, Hussain S, Manu P (2009). Increases in C-reactive protein may predict recurrence of clozapine-induced fever. Ann Pharmacother 43:143-146.
12. Kraus VB, Jordan JM (2006). Serum C-reactive protein (CRP), target for therapy or trouble? Biomarker Insights 1:77-80.
13. Landry P, Benaliouad F, Tessier S (2003). Increased use of antibiotics in clozapine-treated patients. Int Clin Psychopharmacol 18:297-298.
14. Levinson SS (2005). Brief review and critical examination of the use of hs-CRP for cardiac risk assessment with the conclusion that it is premature to use this test. Clin Chim Acta 356:1-8.
15. Levinson SS, Miller JJ, Elin RJ (2004). Poor predictive value of high-sensitivity C-reactive protein indicates need for reassessment. Clin Chem 50: 1733-1735.
16. Müller N, Schwarz M (2006). Schizophrenia as an inflammation- mediated dys-balance of glutamatergic neurotransmission. Neurotoxicity Res 10:131-148.
17. Müller H, Manns M, Hammes E, Hiemke C, Benkert O (1991). Studies on inflammatory side effects of clozapine. Biol Psychiatry 29 (Suppl): 415S-416S; abstract.
18. Müller H, Hammes E, Hiemke C, Benkert O (1992). Influence of clozapine on body temperature and on acute phase proteins. Pharmacopsychiatry 25:109; abstract.
19. Madhusoodanan S, Cuni L, Brenner R, Sajatovic M, Palekar N, Amanbekova D (2007). Chronic leukocytosis associated with clozapine: a case series. J Clin Psychiatry 68:484-487.
20. Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY (1997). In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26:221-225.
21. Marnell L, Mold C, Du Clos TW (2005). C-reactive protein: ligands, receptors and role in inflammation. Clin Inmunol 117:104-111.
22. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM, et al. (2001). Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47:426-430.
23. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. (2003). International suicide prevention trial study group. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 60:82-91.
24. Meyer JM (2002). A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425-433.
25. Moots RJ, Al-Saffar Z, Hutchinson D, Golding SP, Young SP, Bacon PA, et al. (1999). Old drug, new tricks: haloperidol inhibits secretion of proinflam-matory cytokines. Ann Rheum Dis 58:585-587.
26. Newman SC, Bland RC (1991). Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 36:239-245.
27. Park KW, Kwon YW, Cho HJ, Shin JI, Kim YJ, Sang EL, et al. (2008). G-CSF exerts dual effects on endothelial cells-opposing actions of direct eNOS induction versus indirect CRP elevation. JMCC 45:670-678.
28. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 107:499-511.
29. Pepys MB, Hirschfield GM (2003). C-reactive protein: a critical update. J Clin Invest 111:1805-1812.
30. Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, et al. (2009). Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 29:392-394.
31. Pollmächer T, Hinze-Selch D, Mullington J (1996). Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16:403-409.
32. Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D (1997). The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels. Pharmacopsychiatry 30:118-121.
33. Raaska K, Raitasuo V, Arstila M, Neuvonen P J (2002). Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol 58:321-322.
34. Rathore S, Masani ND, Callaghan PO (2007). Clozapine-induced effuso-constrictive pericarditis. Cardiology 108:183-185.
35. Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A, et al. (2005). Increased serum interleukin-1b and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat 1:171-177.
36. Sernyak MJ, Rosenheck R (2004). Clinicians' reasons for antipsychotic copres-cribing. J Clin Psychiatry 65:1597-1600.
37. Shcherbakova I, Neshkova E, Dotsenko V, Platonova T, Shcherbakova E, Yarovaya G (1999). The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacol 43:273-279.
38. Xiaoduo F, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC (2007). Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 149:267-271.
39. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG (2008). Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359:1897-1908.